At a public meeting held on January 15, 2025, the Federal Trade Commission (FTC) summarized the Second Interim Staff Report ...
Mintz’s Health Law and Antitrust teams actively monitor federal and state regulatory and legislative developments in the PBM ...
Pharmacy benefit managers are the middlemen in the prescription drug market. The Federal Trade Commission reports the revenue of four PBMs exceeds $1 trillion and they control 86% of the market.
The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...
In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.
A bipartisan, bicameral group of lawmakers is calling on the Federal Trade Commission (FTC) to vote in favor of releasing an interim staff report on pharmacy benefit managers (PBM). Sens.
The FTC released a 60-page report Tuesday targeting the biggest three pharmacy benefit managers, claiming the companies hiked ...
“The FTC staff’s second interim report finds that ... CEO of 46booklyn — said he’s glad not to be the only one working to expose PBM practices. He said he launched 46brooklyn in 2018 ...
The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying the major industry middlemen generate billions in revenue through ...
Cigna's Evernorth Health Services said on Wednesday its actions will enhance transparency about the company's negotiations.
It is difficult to know the extent of the problems in the PBM market given that there is little in the way of reporting from PBMs and federal agencies like the FTC have only given limited ...